Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (11-20 of 187) with videos related to

Pageof 19
Sort By:
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|February 3, 2011
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective studyFrancesca Palandri, Nicola Polverelli, Lucia Catani, et al.
Frontiers in Oncology|December 3, 2019
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of RuxolitinibElena Maria Elli, Claudia Baratè, Francesco Mendicino, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Leukemia|May 5, 2026
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasmsHaifa K Al-Ali, Sarah T Heidel, Francesca Palandri, et al.
Haematologica|November 21, 2007
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phaseFrancesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, et al.
Leukemia & Lymphoma|July 2, 2025
Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statementMassimiliano Bonifacio, Massimo Breccia, Paola Guglielmelli, et al.
Biologics : Targets & Therapy|August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intoleranceGiovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Pageof 19

Showing results (11-20 of 187) with videos related to

Sort By:
Pageof 19
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Response definitions and European Leukemianet Management recommendationsMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Critical Reviews in Oncology/Hematology|May 14, 2011
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phaseGianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Annals of Hematology|February 3, 2011
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective studyFrancesca Palandri, Nicola Polverelli, Lucia Catani, et al.
Frontiers in Oncology|December 3, 2019
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of RuxolitinibElena Maria Elli, Claudia Baratè, Francesco Mendicino, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Leukemia|May 5, 2026
MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasmsHaifa K Al-Ali, Sarah T Heidel, Francesca Palandri, et al.
Haematologica|November 21, 2007
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phaseFrancesca Palandri, Ilaria Iacobucci, Fabrizio Quarantelli, et al.
Leukemia & Lymphoma|July 2, 2025
Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statementMassimiliano Bonifacio, Massimo Breccia, Paola Guglielmelli, et al.
Biologics : Targets & Therapy|August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intoleranceGiovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Pageof 19